ArticleTranslational psychiatry2026
Long-term trajectories of memory, depression, and mobility independence before death: a multi-cohort study.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive and functional decline are key indicators of mortality risk in older adults. However, temporal onset and progression trajectories of these declines before death, and their cross-national applicability, remain poorly understood. This study aimed to investigate the trajectories of memory performance, depressive symptoms, activities of daily living (ADL), and instrumental activities of daily living (IADL) across four large-scale cohorts: CHARLS (China), ELSA (England), HRS (USA), and SHARE (Europe), to identify patterns associated with imminent mortality. Backward timescale analyses were applied to examine the temporal progression of memory performance, CES-D depressive symptoms, ADL limitations, and IADL impairments leading up to death. Particular attention was given to identifying the onset point and rate of decline associated with mortality. Across the CHARLS, ELSA, HRS, and SHARE cohorts, distinct trajectories in memory performance, depressive symptoms (CES-D scores), ADL, and IADL were observed, highlighting varying patterns associated with mortality as individuals approached death. Memory performance declined significantly in all cohorts, with deceased individuals in CHARLS showing a sharp drop starting 3 years before death (coefficient: -0.0189, p < 0.0001), consistent with trends in ELSA, HRS, and SHARE. CES-D scores progressively increased among deceased individuals, with divergence beginning 6 years before death in CHARLS and 4 years before death in ELSA, peaking at 1 to 2 years before death in most cohorts. ADL scores demonstrated an early decline, with significant differences emerging at 7 years before death in CHARLS and even earlier in HRS (24 years before death), while IADL scores showed more gradual changes, with notable increases in the last 4 to 5 years before death across all cohorts. Memory performance exhibited the strongest association with mortality, followed by ADL scores, emphasizing the critical role of cognitive and functional abilities in end-of-life health trajectories. This study provides cross-national evidence delineating the temporal onset and progression trajectories of cognitive and functional decline before death. Memory performance was the most powerful indicator of imminent mortality, followed by ADL decline. These findings underscore the value of early recognition of declining cognitive and functional abilities among middle-aged and older adults, offering actionable insights for targeted screening, preventive interventions, and end-of-life care planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.